BioLife Solutions (NASDAQ:BLFS) Shares Up 5.4%

BioLife Solutions, Inc. (NASDAQ:BLFS) shares traded up 5.4% during mid-day trading on Thursday . The stock traded as high as $16.04 and last traded at $15.96. 301,339 shares traded hands during mid-day trading, a decline of 25% from the average session volume of 400,998 shares. The stock had previously closed at $15.14.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group initiated coverage on BioLife Solutions in a report on Thursday, April 4th. They issued a “buy” rating and a $22.00 price objective on the stock. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions presently has an average rating of “Moderate Buy” and an average price target of $23.40.

BioLife Solutions Price Performance

The company has a debt-to-equity ratio of 0.06, a current ratio of 2.86 and a quick ratio of 1.83. The business’s 50-day moving average price is $17.44 and its two-hundred day moving average price is $15.34.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, February 29th. The medical equipment provider reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. The firm had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. BioLife Solutions had a negative return on equity of 13.36% and a negative net margin of 46.37%. On average, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.6 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Amy Duross sold 6,135 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $16.86, for a total transaction of $103,436.10. Following the completion of the sale, the director now owns 34,508 shares of the company’s stock, valued at $581,804.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other BioLife Solutions news, Director Amy Duross sold 6,135 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $16.86, for a total transaction of $103,436.10. Following the completion of the transaction, the director now directly owns 34,508 shares in the company, valued at $581,804.88. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CMO Todd Berard sold 10,000 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $15.67, for a total value of $156,700.00. Following the sale, the chief marketing officer now owns 129,644 shares of the company’s stock, valued at $2,031,521.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,702 shares of company stock worth $527,141. Company insiders own 2.70% of the company’s stock.

Institutional Trading of BioLife Solutions

Several large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC raised its stake in BioLife Solutions by 161,879.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 131,203 shares of the medical equipment provider’s stock worth $2,434,000 after acquiring an additional 131,122 shares in the last quarter. Register Financial Advisors LLC acquired a new position in BioLife Solutions during the 1st quarter worth approximately $96,000. Vanguard Group Inc. increased its position in BioLife Solutions by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 2,571,608 shares of the medical equipment provider’s stock worth $41,789,000 after purchasing an additional 30,763 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in BioLife Solutions by 1,038.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,401,899 shares of the medical equipment provider’s stock valued at $39,031,000 after purchasing an additional 2,191,002 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in BioLife Solutions by 6.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,755 shares of the medical equipment provider’s stock valued at $224,000 after buying an additional 858 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.